Ownership and insider activity for Nuvectis Pharma, Inc. (NVCT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Price
| Price | $21.38 |
| Market Cap | $567M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. | A-Award | 30,000 | |
| 2026-06-30 | Mosseri Marlio Charles | P-Purchase | 50,000 | $916K |
| 2026-06-30 | BENTSUR RON | P-Purchase | 12,500 | $250K |
| 2026-06-11 | Hoberman Kenneth | A-Award | 35,000 | |
| 2026-06-11 | Oliviero James F III | A-Award | 35,000 | |
| 2026-06-11 | Sanchez Juan | A-Award | 35,000 | |
| 2026-06-11 | Kaplan Matthew L. | A-Award | 35,000 | |
| 2026-01-06 | Shemesh Shay | A-Award | 150,000 | |
| 2026-01-06 | BENTSUR RON | A-Award | 150,000 | |
| 2026-01-06 | Poradosu Enrique | A-Award | 150,000 |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | $5.8M | $20.4M | $19.2M | $18.6M | $31.7M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0 | $6.7M | $20.4M | $19.2M | $18.6M | $31.7M |
| Accounts Payable | $10000 | $1.1M | $2.9M | $2.8M | $2.5M | $6.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $10000 | $2.4M | $6.2M | $7.0M | $8.9M | $13.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $10000 | $17.7M | $6.2M | $7.0M | $8.9M | $13.3M |
| Retained Earnings | -$10000 | -$12.9M | -$32.0M | -$54.2M | -$73.2M | -$99.7M |
| Total Equity | -$10000 | -$11.0M | $14.2M | $12.2M | $9.7M | $18.4M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 0 | -$5.7M | -$20.0M | -$19.1M | -$18.5M | -$31.6M |
| Working Capital | -$10000 | $3.4M | $14.2M | $12.2M | $9.7M | $18.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.68 |
Profitability
| Return on Equity | -169.47% |
| Return on Invested Capital | -317.86% |
| Return on Assets | -124.45% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARMP · CGEN · CRDF · CYBN · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NVCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks